Finanzen von Actinium Pharmaceuticals Inc (ATNM)ATNMActinium Pharmaceuticals Inc

Evaluating the bottom line, Actinium Pharmaceuticals Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 78.76%, while the net margin is 79.72%. These profitability ratios, combined with a Return on Equity (ROE) of 45.86%, provide a clear picture of how effectively ATNM converts its operational activities into shareholder value.

In the context of the broader market, ATNM competes directly with industry leaders such as NNVC and PPBT. With a market capitalization of $32.70M, it holds a significant position in the sector. When comparing efficiency, ATNM's gross margin of 100.00% stands against NNVC's N/A and PPBT's N/A. Such benchmarking helps identify whether Actinium Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Actinium Pharmaceuticals has demonstrated a significant improvement in financial performance, achieving a net income of $27,901,000 in Q2 2026, a stark contrast to previous losses. The gross margin stands at an impressive 100% for Q2 2026, indicating strong profitability on sales.